AIHTA - Publications - Search - Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer

Gassner, L. and Wild, C. and Hofer, V. (2022): Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer. Decision Support Document 133.

[thumbnail of DSD_133.pdf]
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

This systematic review evaluates whether percutaneous hepatic perfusion is more effective and safer compared to best available care for patients with liver cancer.

One randomised controlled trial and one case series were included. Percutaneous hepatic perfusion might be more effective than best available care in terms of overall progression-free and hepatic progression-free survival. No evidence was identified regarding the quality of life, and overall survival did not improve due to percutaneous hepatic perfusion. Serious, well-recognised complications regarding safety were shown. Three of four deaths were attributed to percutaneous hepatic perfusion. Procedure-related complications were observed in the majority of patients, and many discontinued percutaneous hepatic perfusion.

The available evidence is insufficient and with too limited internal and external validity to demonstrate clinical benefits of percutaneous hepatic perfusion in patients with liver cancer compared to best available care.

Item Type:Decision Support Document
Keywords:Chemosaturation, liver cancer, percutaneous hepatic perfusion
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
W Health professions > W 100-275 Medical, dental and pharmaceutical service plans
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 700-770 Liver. Billary tract
WO Surgery > WO 505 Minimally invasive surgical procedures
Series Name:Decision Support Document 133
Deposited on:15 Jul 2022 09:53
Last Modified:15 Jul 2022 09:53

Repository Staff Only: item control page